Last reviewed · How we verify
Apremilast IR
At a glance
| Generic name | Apremilast IR |
|---|---|
| Also known as | Otezla® |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Diarrhoea
- Nausea
- Myalgia
- Pain
- Muscle spasms
- Fatigue
- Abdominal pain
- Dyspepsia
- Vomiting
- Arthralgia
- Dizziness
Key clinical trials
- A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apremilast IR CI brief — competitive landscape report
- Apremilast IR updates RSS · CI watch RSS
- Amgen portfolio CI